JP2019529959A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529959A5 JP2019529959A5 JP2019538737A JP2019538737A JP2019529959A5 JP 2019529959 A5 JP2019529959 A5 JP 2019529959A5 JP 2019538737 A JP2019538737 A JP 2019538737A JP 2019538737 A JP2019538737 A JP 2019538737A JP 2019529959 A5 JP2019529959 A5 JP 2019529959A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- superoxide production
- chemiluminescence
- subject
- neutrophils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 35
- 201000011510 cancer Diseases 0.000 claims description 27
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 19
- 210000000440 neutrophil Anatomy 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 10
- 206010027476 Metastases Diseases 0.000 claims description 9
- 230000009401 metastasis Effects 0.000 claims description 7
- 239000000411 inducer Substances 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 3
- 230000000638 stimulation Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 206010065305 Cancer in remission Diseases 0.000 description 1
- 101710091342 Chemotactic peptide Proteins 0.000 description 1
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine Proteins 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- PRQROPMIIGLWRP-BZSNNMDCSA-N chemotactic peptide Chemical compound CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-BZSNNMDCSA-N 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1616640.7A GB201616640D0 (en) | 2016-09-30 | 2016-09-30 | Monitoring cancer recurrence and progression |
| GB1616640.7 | 2016-09-30 | ||
| PCT/GB2017/052947 WO2018060741A1 (en) | 2016-09-30 | 2017-10-02 | Monitoring cancer recurrence and progression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529959A JP2019529959A (ja) | 2019-10-17 |
| JP2019529959A5 true JP2019529959A5 (https=) | 2020-11-12 |
| JP7065862B2 JP7065862B2 (ja) | 2022-05-12 |
Family
ID=57570942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538737A Active JP7065862B2 (ja) | 2016-09-30 | 2017-10-02 | 癌の再発および進行のモニタリング |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11435341B2 (https=) |
| EP (1) | EP3519813B1 (https=) |
| JP (1) | JP7065862B2 (https=) |
| CN (1) | CN109791141B (https=) |
| DK (1) | DK3519813T3 (https=) |
| ES (1) | ES2881810T3 (https=) |
| GB (1) | GB201616640D0 (https=) |
| WO (1) | WO2018060741A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220308046A1 (en) | 2019-06-27 | 2022-09-29 | Binary Llc | Oxidase-based chemiluminescence assay of phagocytic leukocytes in whole blood and body fluids applicable to point-of-care (poc) diagnostic testing point-of-care (poc) measurement of absolute neutrophil function (anf) |
| JP2023554149A (ja) * | 2020-12-22 | 2023-12-26 | セロクソ リミテッド | 敗血症を診断およびモニターする方法 |
| GB2619197B (en) * | 2021-02-02 | 2025-12-17 | Seroxo Ltd | Monitoring COVID-19 progression and treatment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159683A (en) * | 1997-12-16 | 2000-12-12 | Spectral Diagnostics, Inc. | Method of determining stage of sepsis |
| CA2442741A1 (en) | 2001-03-27 | 2003-01-16 | Human Genome Sciences, Inc. | Human secreted proteins |
| GB0225885D0 (en) | 2002-11-06 | 2002-12-11 | Isis Innovation | Quantifying exposure to stress |
| EP1799867A2 (en) | 2004-09-23 | 2007-06-27 | Vasgene Therapeutics, Inc. | Compositions and methods for detecting and treating tumors |
| AT504232A1 (de) | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prognostische parameter |
| WO2008074131A1 (en) | 2006-12-20 | 2008-06-26 | Mcmaster University | Skin and salivary tests for the detection of sensitivity to oxidative stress based therapies |
| JP5785081B2 (ja) * | 2008-09-05 | 2015-09-24 | エー アンド ジー ファーマシューティカル，インコーポレイテッド | Ｇｐ８８結合性組成物 |
| US9199028B2 (en) | 2010-01-15 | 2015-12-01 | Memorial Sloan-Kettering Cancer Center | Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients |
| US20140127179A1 (en) * | 2012-11-02 | 2014-05-08 | Scientific Formulations, Llc | Natural Killer Cell Formulations |
-
2016
- 2016-09-30 GB GBGB1616640.7A patent/GB201616640D0/en not_active Ceased
-
2017
- 2017-10-02 JP JP2019538737A patent/JP7065862B2/ja active Active
- 2017-10-02 WO PCT/GB2017/052947 patent/WO2018060741A1/en not_active Ceased
- 2017-10-02 EP EP17784992.4A patent/EP3519813B1/en active Active
- 2017-10-02 ES ES17784992T patent/ES2881810T3/es active Active
- 2017-10-02 DK DK17784992.4T patent/DK3519813T3/da active
- 2017-10-02 CN CN201780060988.2A patent/CN109791141B/zh active Active
- 2017-10-02 US US16/337,035 patent/US11435341B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020028300A5 (https=) | ||
| Ye et al. | Precise detection and quantitative prediction of blood glucose level with an electronic nose system | |
| Nelzen | Prevalence of venous leg ulcer: the importance of the data collection method | |
| JP6100867B1 (ja) | 免疫状態の分析のための検査方法 | |
| JP2016500110A5 (https=) | ||
| RU2014120427A (ru) | Определение микрорнк в плазме для обнаружения ранних стадий колоректального рака | |
| JP2015523569A5 (https=) | ||
| JP2017508970A5 (https=) | ||
| JP2023538944A (ja) | 前立腺がん対象者の治療に対する応答の予測又は前立腺がん対象者の治療の個人化 | |
| JP2019529959A5 (https=) | ||
| JP6064039B2 (ja) | 低レベル電離放射線に敏感な遺伝子の検出方法及び該方法により検出された遺伝子 | |
| AU2022277600A1 (en) | Predictive mirnas for response to cancer therapy | |
| Diebold et al. | Neurokinin A levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms | |
| Vinayanuwattikun et al. | Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer | |
| JP7065862B2 (ja) | 癌の再発および進行のモニタリング | |
| KR102216725B1 (ko) | 면역 항암 요법에 대한 치료 반응 예측 방법 | |
| Liefaard et al. | RNA signatures from tumor-educated platelets (TEP) enable detection of early-stage breast cancer | |
| Niblock et al. | Assessing the frequency of CD163+ tumor-associated macrophages and CD3+ T lymphocytes between MGUS and plasma cell myeloma | |
| Demircioglu et al. | Lymph node ratio assessment of brain metastasis in early breast cancer cases | |
| JP2016080672A (ja) | 悪性リンパ腫の検出法 | |
| WO2015105917A1 (en) | Biomarker for human prostate cancer | |
| Rock et al. | Development and validation of a gene expression signature to distinguish malignant melanoma from benign nevi | |
| Gür et al. | Predictive factors for lymph node metastasis and the effect on survival in early gastric cancer patients with radical gastric resection | |
| Rosenthal et al. | Detector-c 2.0: a highly accurate blood-based IVD test for early detection of colorectal cancer with sensitivity and specificity over 90% | |
| CN106932580B (zh) | Hsp90AB1蛋白在预测肺癌预后风险的诊断模型中的应用 |